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SUMMARY 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are very widely prescribed but they have a 
poor safety profile, with a range of potential adverse effects. NSAIDs that are used in topical 
formulation have been developed in the last fifteen years and their use is increasing. The 
purpose is to achieve a high local concentration of the active ingredient at the affected site, 
with as low a plasma concentration as possible to minimise possible systemic side-effects. 
This paper reviews the evidence available regarding the safety of topical NSAIDs, with 
particular reference to gastrointestinal and renal toxicity which have recently been 
highlighted in the medical press. The effects on the elderly are also discussed. The authors 
conclude that more formal epidemiological evaluation of the safety of topical NSAIDs is 
required in the post-marketing situation.   
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed 
drugs world-wide. There are about 20 million prescriptions dispensed per year in the UK at a 
1993 cost of over £180m{1}. In Tayside, Scotland, which has a population of nearly 400 
thousand people, 150 thousand patients received 736 thousand prescriptions for NSAIDs in 
the five year period from 1989 to 1993. Over one quarter of the patients receiving NSAID 
prescriptions were elderly, and they recived almost one half of the NSAID prescriptions 
(Table 1). The prevalence of NSAID use was calculated by determining the percentage of the 
population who dispensed at least one NSAID between 1989 and 1993, using mid-1991 
population estimates{1083}. This was nearly 60% in the elderly. 
 
That NSAIDs are useful in the treatment of rheumatoid arthritis and other inflammatory 
arthropathies is beyond doubt{399}, but they are frequently associated with serious or life 
threatening adverse reactions and are responsible for a quarter of all serious adverse drug 
reactions reported to the Committee on Safety of Medicines (CSM) on Yellow Cards{615}. 
Indeed, enteral NSAIDs appear to be associated with toxicity of similar magnitude to second-
line drugs{1812}. 
 
SIDE-EFFECTS OF ORAL NSAIDS 
 
The main adverse drug reactions occurring with NSAIDs, with particular reference to the 
elderly, have been described in a recent review{1771}. 
 
Gastrointestinal toxicity 
 
In broader populations, the toxicity of NSAIDs on the upper{498}{136}{466}{1397}{129} 
and lower{1137}{518}{401} gastrointestinal tract is well documented. Such gastrointestinal 
mucosal damage is the result of the inhibition of prostaglandin synthesis{517}. Patients 
exposed to NSAIDs therefore have an increased risk of serious complications from peptic 
ulcer disease. The incidence of NSAID-induced erosions and concomitant haemorrhage and 
perforation ranges from 6,000 to 20,000 each year in the UK{1390}. Increasing age increases 
both the relative and absolute risk of NSAID-induced upper gastrointestinal 
damage{554}{517} because elderly patients already have a higher background risk{517}.   
 
Renal side-effects 
 
NSAIDs may also cause renal impairment leading to acute and chronic renal failure{1008}. 
Although earlier pharmacoepidemiological studies failed to show any risk or showed that the 
risk was low{1015}, evidence is now available from randomised controlled studies{1011} 
and observational studies{1107}. In addition, a recent study carried out using an automated 
database at the Medicines Monitoring Unit, University of Dundee (MEMO){1766} found an 
approximate doubling of the risk of hospitalisation for acute renal failure with the use of 
NSAIDs{1401}. The elderly appear more susceptible to renal toxicity, probably due to 
reduced renal reserve{1108}.   
 
Hepatotoxicity 
 
NSAID-induced hepatotoxicity is a well-recognised but rare adverse effect{1729}. One 
recent cohort study found that current NSAID users have twice the background risk of newly 
diagnosed acute liver injury{544}. In this study, the rate ratio was the same across all age 
groups. However, NSAID induced liver damage is more common among elderly patients, 
because they have a higher background rate and are more likely to be exposed to NSAIDs. 
For example, among 70 cases of acute liver disorder{1729}, a causal effect of NSAIDs could 
not be ruled out for nine. Of these nine, six were over the age of 60 years. 
 
Other effects 
 
NSAIDs raise blood pressure{1148} and their use results in increased prescribing of 
antihypertensive drugs{1146}. They have haematological effects, notably decreased platelet 
adhesiveness and increased risk of bleeding{4}. NSAIDs can also cause hypersensitivity 
reactions and rashes{4}, and worsening of osteoarthritis{1809}. They may also be toxic to 
the bone marrow{1811}. Since 1975, the CSM has been aware that NSAIDs can cause 
bronchospasm in susceptible patients{100}, and the British National Formulary contains a 
CSM warning that any degree of worsening of asthma may be associated with NSAID 
ingestion{762}. As with all drugs, the possibility of NSAIDs causing confusion in the elderly 
should also be considered{1771}. 
 
Interactions 
 
There are many NSAID-drug interactions{101}, in which the NSAID is often the activating 
agent{1771}. This is a particular problem in the elderly, partly as a result of polypharmacy, 
and they require close monitoring.  
 
There is now good evidence that NSAID toxicity is dose related, and that some NSAIDs are 
more toxic than others{136}{436}{1359}. 
 STRATEGIES FOR REDUCING NSAID TOXICITY 
 
The toxicity of NSAIDs could be reduced in several ways. First, it has been suggested that 
many patients with osteoarthritis could be managed with simple analgesics rather than 
NSAIDs{1773}{1813}{1829}. Presumably such advice could be extended to include the 
symptomatic treatment of simple musculoskeletal symptoms where an anti-inflammatory 
action is not required.  
 
Second, where an NSAID is indicated, the lowest effective doses of the least toxic NSAIDs 
should be used{1350}. 
 
There are some patients at high risk from NSAID toxicity but for whom no other therapy can 
be given. These include the elderly and those either with symptoms or a history of an upper 
gastrointestinal disorder. In such cases prophylactic therapy with prostaglandin analogues, 
shown to reduce serious upper gastrointestinal complications{1810}, or other ulcer healing 
drugs, not yet shown unequivocally to reduce upper gastrointestinal haemorrhage{506}, 
should be used.  
 
These strategies apply equally to patients receiving NSAIDs for the first time and those 
receiving chronic prescriptions, as the risk from NSAIDs is probably constant with 
continuous exposure{1669}.  
 
Topical NSAIDs 
 
Another alternative is to prescribe NSAIDs in topical formulation. The development, over the 
last fifteen years, of NSAID preparations that are administered topically has been welcomed 
from a safety standpoint. Fig 1 shows that use of topical NSAIDs has increased in Tayside in 
the elderly population between 1989 and 1993. Table 2 shows utilisation and prevalence by 
age and sex for the same time period, and it is clear that although topical NSAIDs are used 
less commonly than oral NSAIDs, there is still the same pattern of increased use in the 
elderly.   
 
The rationale behind using NSAIDs in topical formulation is to achieve a high local 
concentration of the active ingredient at the affected site, with as low a plasma concentration 
as possible in order to minimise systemic side-effects{1768}. The short distance of 
transmission from the site of application (the skin) to the target (the joint), and the avoidance 
of the entero-hepatic cycle, is an attractive concept. While first generation topical NSAIDs 
achieved plasma levels of 5-10% of those reached with oral NSAIDs, this figure is less than 
2% for some of the second generation topicals{1769}. Although some studies have shown 
that topical NSAIDs are more effective than placebo at providing relief for a range of 
indications{1242}{1248}{1776}{1247}{598}, they have not been extensively tested against 
oral analgesics{602}. There is widespread, if not substantiated, opinion that topical NSAIDs 
are clinically less effective than oral NSAIDs{1350}{1768}. However, it is the safety of 
topical NSAIDs rather than the efficacy, particularly in the elderly, that is the topic of this 
article. This is becoming progressively more important as the use of topical NSAIDs 
increases. To date, no topical NSAID has had its license withdrawn due to serious side-
effects, in contrast to the oral NSAID experience{334}{335}{1814}. 
 
ADVERSE EFFECTS OF TOPICAL NSAIDS 
 Dermatological effects 
 
Local skin sensitivity, contact dermatitis and photodermatitis are well recognised adverse 
effects of topical NSAIDs. These are common enough to be detected in small randomised 
clinical trials. A review of four topical NSAIDs found the highest reported incidence of such 
skin reactions was 2.6%{3}. It is therefore advised that they are not used on broken or 
inflamed skin{762}.  
 
Systemic Side-Effects 
 
One important question is whether or not the plasma concentrations produced by topical 
NSAIDs are high enough to cause systemic side-effects of the same nature as those of oral 
NSAIDs. The British National Formulary contains a caution that topical application of large 
amounts of these drugs may result in systemic side-effects, including hypersensitivity and 
asthma{762}. They are thus contraindicated in patients with known hypersensitivity to 
NSAIDs{1768}{468}. 
 
Several investigators have reported either a low or no incidence of systemic side-effects in 
randomised controlled trials of patients exposed to topical NSAIDs. It should be pointed out, 
however, that these studies involved small numbers of patients and elderly patients were 
excluded{1077}{1242}{1248}{1776}{602}{1247}. In a post-marketing surveillance study 
of 23,590 patients exposed to felbinac 5% gel (which was probably more representative of 
the real-life situation in which these drugs are used and had a patient age range of eight to 
103 years) 327 patients experienced 331 adverse events{468}. Although the majority were 
skin reactions, 24 were related to the gastrointestinal tract. There were eight serious adverse 
reactions, one of which was “probably” related to topical NSAID use. Unfortunately, this 
report does not detail the ages of the patients who experienced these adverse effects.    
 
The main source of information regarding adverse drug reactions to topical NSAIDs in the 
United Kingdom has been data from Yellow Card reports to the CSM{439}. These data 
should be viewed critically as we have no knowledge of the overall numbers of patients 
exposed to the drugs. However, it is worth noting that up to October 1994, there had been a 
total of 500 reports of adverse reactions following the topical application of diclofenac, 
ibuprofen, ketoprofen, piroxicam or felbinac (personal communication, CSM). None of these 
reactions were fatal, and 54% were skin or subcutaneous tissue disorders, but over one third 
of the rest were gastrointestinal effects. It was not possible to determine how many of these 
reactions were confounded by any additional medication being taken, in particular, oral 
NSAIDs.  
 
Upper gastrointestinal toxicity 
 
To assess the independent epidemiological risk of upper gastrointestinal bleeding and 
perforation associated with topical NSAID use, we have carried out a case-control study in a 
population of approximately 400,000 people, using the MEMO databases{1400}. There were 
1,103 cases in the study, and the effect of confounding from oral NSAIDs and ulcer healing 
drugs was removed by conditional logistic regression. The adjusted odds ratios were 1.43 
(0.81 - 2.54) and 1.05 (0.57 - 1.92) using community and hospital controls respectively. We 
concluded that the independent risk from topical NSAIDs was minimal. We have since 
repeated the study in a population of patients over the age of 65 years (unpublished data). We 
should stress that this analysis is not independent as we used a proportion of the cases from 
the earlier study (a total of 665), but the adjusted odds ratios for the independent effect of 
topical NSAIDs were slightly higher, 1.74 (1.01 - 3.01) and 1.78 (0.91 - 3.46) using 
community and hospital controls respectively. This suggests that in an elderly population, 
topical NSAIDs may carry a small risk of gastrointestinal side-effects. 
 
Renal side-effects 
 
Up to October 1994, there had been five reports to the CSM of renal dysfunction following 
use of topical NSAIDs (personal communication, CSM). These were one each of acute renal 
failure, aggravated chronic renal failure, interstitial nephritis, nephrotic syndrome/nephrosis 
and urinary incontinence. There have also been case reports in the literature of renal 
impairment associated with topical NSAID use{1112}{1017}. We conducted a case-control 
study to address this issue, evaluating the independent effect of topical NSAIDs using 207 
cases hospitalised with acute renal failure{1401}. The odds ratios for ever exposure, adjusted 
for oral NSAID use, were 1.33 (0.79, 2.24) and 1.04 (0.60, 1.83) using community and 
hospital controls respectively. We concluded that the independent risk of acute renal failure 
from topical NSAIDs was minimal. When the analyses were repeated using 139 cases over 
the age of 65 years (unpublished data), the risks were 1.15 (0.61 - 2.18) and 0.60 (0.31 - 1.16) 
and did not suggest that topical NSAIDs carry an independent risk of acute renal failure in the 
elderly.  
 
Other systemic effects 
 
There is scarce epidemiological data available regarding the other less commonly occurring 
adverse drug reactions associated with oral NSAID use, which may also be associated with 
topical NSAIDs. Up to October 1994, there had only been one case reported to the CSM of 
abnormal hepatic function following topical NSAID use (personal communication, CSM). 
There had been a handful of reports of haemopoitetic disorders (one of thrombocytopenia, 
and two of increased international normalised ratio which may have been the result of 
interactions), and a slightly higher number of reports of cardiovascular disorders (personal 
communication, CSM). These included ten reports of peripheral oedema and four of 
palpitations. In contrast, the number of reports of respiratory disorders is high, 49 in total 
(personal communication, CSM). These included 19 cases of bronchospasm, 15 of 
aggravated asthma and ten of breathlessness. However, the problem was specifically 
highlighted in a CSM publication of December 1989{599} and it may be that this prompted 
doctors to report more readily than they would have done so otherwise. In the post-marketing 
study of felbinac 5% gel, there was one case of bronchospasm, judged to be “probably” 
related to topical NSAID use, among 23,590 exposed patients{468}.   
 
While the overall safety of topical NSAIDs seems reasonable, the data available are 
incomplete. The main source of information available is spontaneous reporting Yellow Card 
data{327}, which is flawed from an epidemiological point of view. The main problems 
include under-reporting and lack of knowledge regarding the denominator (the total numbers 
of patients exposed to the drugs){462}, doctors having variable reporting thresholds and 
rates{916}, and biased reporting and increased reporting following media attention{1419}. 
More formal epidemiological evaluation in the post-marketing situation is required to assess 
the real risks of these drugs. 
 
There is evidence to suggest that the elderly are at higher risk of drug toxicity{661}{1771}. 
There is more individual variability in pharmacokinetic and pharmacodynamic response in 
the elderly{660}, they usually take more drugs, including over the counter medications, thus 
increasing the likelihood of interactions{660}, and compliance may be poor{160}. The risks 
from topical NSAIDs are probably dose-related. It may be that the thin epidermal layers of 
elderly patients have a high rate of absorption. In conclusion, there is little doubt that topical 
NSAIDs are safer than oral NSAIDs, but they may not be entirely risk-free, and as with all 
drugs, they should be prescribed with caution in elderly patients. We strongly recommend 
that more post-marketing surveillance data is accumulated regarding the safety of topical 
NSAIDs. These should be conducted in as wide a variety of study settings as possible, 
according to the Safety Assessment of Marketed Medicines Guidelines{1533}.  
 
 
 Males Females Total 
 Patients Scripts Patients Scripts Patients Scripts Prevalence 
0-14 yrs 1,762 2,407 2,532 3,903 4,294 6,310 6% 
15-44 yrs 26,523 61,273 38,310 98,964 64,833 160,237 39% 
45-64 yrs 21,159 94,007 28,144 161,006 49,303 255,013 56% 
65+ yrs 14,236 101,285 24,846 213,164 39,082 314,449 59% 
Total 61,040 258,972 89,035 477,037 150,075 736,009 38% 
 
Table 1  
  
 Males Females Total 
 Patients Scripts Patients Scripts Patients Scripts Prevalence 
0-14 yrs 680 741 671 763 1,351 1,504 2% 
15-44 yrs 4,569 5,581 6,303 8,036 10,872 13,617 7% 
45-64 yrs 4,452 7,519 7,339 13,947 11,791 21,466 13% 
65+ yrs 4,545 12,019 9,818 29,855 14,363 41,874 22% 
Total 14,071 25,860 23,776 52,601 37,847 78,461 10% 
 
Table 2 
Legend to Tables 
 
Table 1: Utilisation and prevalence of oral NSAIDs in the Tayside population by age and sex 
1989-1993 
 
Table 2: Utilisation and prevalence of topical NSAIDs in the Tayside population by age and 
sex 1989-1993 
 
 
 
